The disclosure provides bone graft materials, methods for their use and manufacture. Exemplary bone graft materials comprise combining a radiopaque component with a cancellous bone component to produce a bone graft material, wherein the cancellous bone component comprises native osteoreparative cells. Methods for treating a subject with the bone graft material are also provided.

The present disclosure relates to injectable and expandable compositions, devices, kits and methods for use in an approach for the in-situ foaming of polymers for bone or tissue defects, namely to fill and/or fuse a tissue defect. The present disclosure relates to compositions, devices, kits and methods for use in an approach for the in-situ foaming of polymers for bone or tissue defects, namely for bone tissue defect filling/fusion. The design of extendable and expandable compositions for bone fusion is one of the most challenging fields in the intersection of polymer and biomedical engineering. An aspect of the present disclosure relates to an injectable expandable composition for use in medicine, veterinary or cosmetic, comprising a polycaprolactone particle filler; a polydopamine adhesive bound to said filler; a polymethacrylic acid plasticizer bound to said polydopamine adhesive.

A dynamic disc assembly has a superior end plate, an inferior end plate, and a core. The core has surfaces of an annular Fresnel shape and a linear Fresnel-like shape combined to control the dynamic range of motion (ROM) movement arranged to match anatomical ROM. The core is interposed between and held against interior surfaces of the superior end plate and the inferior end plate. The assembly further has a pair of coupling cords, one coupling cord at each lateral end of the superior and inferior end plates wherein each lateral end of each end plate has one or more cord connections attached and affixed to the coupling cord to form and retain the dynamic disc assembly.

An autologous bone graft substitute composition for inducing new bone formation, promoting bone growth and treating bone defects. The composition includes autologous blood; one or more analogs of an osteogenic bone morphogenetic protein selected from BMP-6, BMP-2, BMP-7, BMP-4, BMP-5, BMP-8, BMP-9, BMP-12, and BMP-13, and combinations thereof in a range of from 2 to 1000 μg per ml of autologous blood; and hydroxyapatite, tri-calcium phosphate, or a mixture thereof as a compression resistant matrix, the compression resistant matrix being provided in the form of particles having a particle size in a range of from above 74 to 8000 μm. Preferably, a ratio between the compression resistant matrix and the autologous blood coagulum is from 50 to 500 mg of the compression resistant matrix per mL of the autologous blood coagulum.

An hydrogel comprising chitosan and two weak bases having different pKb values. In some embodiments, one of the weak bases if sodium hydrogen carbonate (SHC). Also, use of the hydrogel in medical and cosmetic treatments.

A three-dimensional, biocompatible scaffold precursor composition for room-temperature printing a bio-compatible polymer/hydroxyapatite composite scaffold includes a room-temperature slurry, comprising a mixture of a sold phase that includes a mixture of tetracalcium phosphate (TTCP; Ca.sub.4(PO.sub.4).sub.2O) and dicalcium phosphate anhydrous (DCPA; CaHPO.sub.4), and a liquid phase that includes a polymer in a solvent. The solvent may be Ethanol (EtOH) or Tetrahydrofuran (THF), and the polymer may be polyvinyl butyral (PVB), polycaprolactone (PCL), or poly lactic-co-glycolic acid (PLGA). The slurry is printed at room temperature in aqueous phosphate (NaH.sub.2PO.sub.4) bath, which works as hardening accelerator, forming the polymer/hydroxyapatite composite scaffold.

The present disclosure provides a bio-material composition and method of use in craniomaxillofacial surgery. An example method comprises: accessing a space defined between adjacent bone structures in a head of a patient; mixing magnesia, potassium biphosphate, and a calcium phosphate with an aqueous solution to form an activated bone fusion slurry (ABFS); applying an effective amount of the ABFS to the space between the adjacent bone structures; allowing the ABFS to set forming a bonded bone structure; and permitting bone growth into the bonded bone structure providing fusion of the two adjacent bone structures, wherein the ABFS promotes fusion of the two adjacent bone structures without the need for additional physical fixation devices.

The present disclosure relates to hydrogels and their use for repairing or supplementing body tissue. The hydrogels are capable of safe injection into patients through fine gauge needles and are suitable for repairing, supplementing, or replacing the nucleus pulposus of an intervertebral disc. Methods of manufacturing and methods of using the hydrogels of the present disclosure to repair or replace tissues are also disclosed.

A method of manufacturing a resorbable, macroporous bioactive glass scaffold comprising approximately 15-45% CaO, 30-70% SiO.sub.2, 0-25% Na.sub.2O, 0-17% P.sub.2O.sub.5, 0-10% MgO and 0-5% CaF.sub.2 by mass percent, produced by mixing with pore forming agents and specified heat treatments.

A method of making a hydroxyl-terminated thioketal diol is provided, the method comprising reacting a thioketal ester with a non-pyrophoric reducing agent to form a hydroxyl-terminated thioketal diol. The hydroxyl-terminated thioketal diol can be 2,2-(propane-2,2-diylbis(sulfanediyl)) diethanol. The non-pyrophoric reducing agent can be a sodium aluminum hydride, for example, sodium bis (2-methoxyethoxy)aluminum hydride. The thioketal ester can be dimethyl 2,2-(propane-2,2-diylbis(sulfanediyl)) diacetate. A biodegradable matrix prepared by reacting a hydroxyl-terminated thioketal diol with an isocyanate is provided. A method of making a biodegradable polyurethane composite is also provided.